10.30.12
Charles River Laboratories
3Q Revenues: $278.7 million (flat)
3Q Earnings: $22.2 million (+17%)
YTD Revenues: $849.4 million (flat)
YTD Earnings: $79.3 million (-4%)
Comments: Research Models and Services (RMS) segment sales were $166.5 million in the quarter, down 3%. Preclinical Services (PCS) sales were $112.2 million, up 6%. Income from continuing operations for the quarter was $22.4 million, compared to $18.9 million in 3Q11.
3Q Revenues: $278.7 million (flat)
3Q Earnings: $22.2 million (+17%)
YTD Revenues: $849.4 million (flat)
YTD Earnings: $79.3 million (-4%)
Comments: Research Models and Services (RMS) segment sales were $166.5 million in the quarter, down 3%. Preclinical Services (PCS) sales were $112.2 million, up 6%. Income from continuing operations for the quarter was $22.4 million, compared to $18.9 million in 3Q11.